Recreational ecstasy use and depression

Journal of Psychopharmacology

Volumn 20, Issue 3, 2006, Pages 411-416

  Guillot, Casey ^a   Greenway, David ^a  

^a UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Beck Depression Inventory; Depression; Ecstasy; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; RECREATIONAL DRUG;

ADULT; ARTICLE; AXONAL INJURY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; FEMALE; HUMAN; MALE; MENTAL DISEASE; MOOD DISORDER; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PERSONALITY INVENTORY; PSYCHOMETRICS; REFERENCE VALUES; SEROTONIN AGENTS; STREET DRUGS;

EID: 33645732202     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106063265     Document Type: Article

References (58)

1. Al-Musawi, Nu'man M (2001) Psychometric properties of the Beck Depression Inventory-II with university students in Bahrain. J Pers Assess 77: 568-579
2. Baron P, Hanna J (1990) Egocentrism and depressive symptomatology in young adults. Soc Behav Pers Int J 18: 279-285
3. Beck A T, Steer R A, Brown G K (1996) Beck Depression Inventory-II manual. The Psychological Corporation, San Antonio, TX
4. Beck A T, Steer R A, Garbin M G (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8: 77-100.
5. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of 'ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189
6. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384
7. Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531-1536
8. Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden, L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345
9. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol Clin Exp 16: 627-633
10. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 173: 398-404
11. de Almeida S P, Silva M T A (2005) Characteristics of ecstasy users in Sao Paulo, Brazil. Subst Use Misuse 40: 395-404
12. de Win M M L, Reneman L, Reitsma J B, den Heeten G J, Booij J, van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users: the influence of long-term abstention, dose, and gender. Psychopharmacology 173: 376-382
13. Dobson K S, Breiter H J (1983) Cognitive assessment of depression: reliability and validity of three measures. J Abnorm Psychol 92: 107-109
14. Dozois D J A (2003) The psychometric characteristics of the Hamilton Depression Inventory. J Pers Assess 80: 31-40
15. Dughiero G, Schifano F, Forza G (2001) Personality dimensions and psychopathological profiles of ecstasy users. Hum Psychopharmacol Clin Exp 16: 635-639
16. Falck R S, Wang J, Carlson R G, Siegal H A (2006) Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio. Addict Behav 31: 90-101
17. Gotlib I H (1984) Depression and general psychopathology in university students. J Abnorm Psychol 93: 19-30
18. Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327
19. Grinspoon L, Bakalar J B (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40: 393-404
20. Halpern J H, Pope H G, Sherwood A R, Barry S, Hudson J I, Yougelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147
21. Lieb R, Schuetz C G, Pfister H, von Sydow K, Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68: 195-207
22. Lightfoot S L, Oliver J M (1985) The Beck Inventory: psychometric properties in university students. J Pers Assess 49: 434-436
23. MacInnes N, Handley S L, Harding GFA (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15: 181-186
24. McCann U D, Ricaurte G A (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24: 333-334
25. McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 352: 1433-1437
26. 11C]DASB. Neuropsychopharmacology 30: 1741-1750
27. McCardle K, Luebbers S, Carter J D, Croft R J, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173: 434-439
28. Milani R M, Parrott A C, Turner J J D, Fox H C (2004) Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 29: 965-971
29. Morgan M J, McFie L, Fleetwood L H, Robinson J A (2002) ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159: 294-303
30. National Institute of Mental Health (2002) Medications (Publication No. 02-3929). Retrieved 27 September 2004, from http://www.nimh.nih.gov/publicat/ medicate.cfm
31. O'Hearn E, Battaglia G, De Souza E B, Kuhar M J, Molliver M E (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
32. Parrott A C (2004) Is ecstasy MDMA? a review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 173: 234-241
33. Parrott A C, Sisk E, Turner J J D (2000) Psychobiological problems in heavy ecstasy (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110
34. Parrott A C, Milani R M, Parmar R, Turner J J D (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159: 77-82
35. Reneman L, Lavalaye J, Schmand B, de Wolff F A, van den Brink W, den Heeten G J (2001a) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylene-dioxymethamphetamine (MDMA or ecstasy): preliminary findings. Arch Gen Psychiatry 58: 901-906
36. Reneman L, Booij J, de Bruin K, Reitsma J B, de Wolff F A, Gunning W B, den Heeten G J, van den Brink W (2001b) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869
37. Ricaurte G A, DeLanney L E, Irwin I, Langston J W (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446: 165-168
38. Ricaurte G A, Martello A L, Katz J L, Martello M B (1992) Lasting effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622
39. Rizley R (1978) Depression and distortion in the attribution of causality. J Abnorm Psychol 87: 32-48
40. Robbins P R, Tanck R H (1984) The Beck Depression Inventory and self-reports of behavior over a ten-day period. J Pers Assess 48: 42-45
41. Robinson L A, Berman J S, Neimeyer RA (1990) Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol Bull 108: 30-49
42. Roiser J P, Sahakian B J (2004) Relationship between ecstasy use and depression: a study controlling for polydrug use. Psychopharmacology 173: 411-417
43. Semple D M, Ebmeier K P, Glabus M F, O'Carroll R E, Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (ecstasy) users. Br J Psychiatry 175: 63-69
44. Shipley W C (1940) A self-administering scale for measuring intellectual impairment and deterioration. J Psychol 9: 371-377
45. Steer R A, Clark D A (1997) Psychometric characteristics of the Beck Depression Inventory-II with college students. Meas Eval Couns Dev 30: 128-136
46. Storch E A, Roberti J W, Roth D A (2004) Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students. Depress Anxiety 19: 187-189
47. Sumnall H R, Cole J C (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol 19: 84-92
48. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96
49. Verheyden S L, Henry J A, Curran H V (2003) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol Clin Exp 18: 507-517
50. Verkes R J, Gijsman H J, Pieters M S M, Schoemaker R C, de Visser S, Kuijpers M, Pennings E J M, de Bruin D, Van de Wijngaart G, Van Gerven J M A, Cohen A F (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153: 196-202
51. Vollenweider F X, Jones R T, Baggott M J (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24: 461-463
52. Vollenweider F X, Gamma A, Liechti M, Huber T (1999) Is a single dose of MDMA harmless? Neuropsychopharmacology 21: 598-600
53. von Geusau N A, Stalenhoef P, Huizinga M, Snel J, Ridderinkhof K R (2004) Impaired executive function in male MDMA ('ecstasy') users. Psychopharmacology 175: 331-341
54. Weiss J L, Schell R E (1991) Estimating WAIS-R IQ from the Shipley Institute of Living Scale: a replication. J Clin Psychol 47: 558-562
55. Whisman M A, Perez J E (2000) Factor structure of the Beck Depression Inventory-Second Edition (BDI-II) in a student sample. J Clin Psychol 56: 545-551
56. Wilson M A, Ricaurte G A, Molliver M E (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28: 121-137
57. Zachary R A (1991) Revised manual for the Shipley Institute of Living Scale. Western Psychological Services, Los Angeles
58. Zachary R A, Crumpton E, Spiegel D E (1985) Estimating WAIS-R IQ from the Shipley Institute of Living Scale. J Clin Psychol 41: 532-540